Heart failure (HF) is a principal cause of global mortality and disability. Atherosclerotic coronary disease and hypertension are two major risk factors for the incidence and progress of HF. Despite marked improvement in the management of the risk factors, the prevalence of HF continues to rise rapidly.
Understanding the pathogenesis of atherosclerosis and hypertension is essential to control the occurrence and progress of these diseases, which is helpful for reducing HF events caused by atherosclerosis and hypertension. Endothelial to mesenchymal transition (EndMT), characterized by decreasing endothelial properties and acquiring of mesenchymal features, plays a vital role in many cardiovascular diseases referring to the pathophysiology of atherosclerotic plaque formation and rupture, vascular or ventricular remodeling, etc. Furthermore, it is necessary to identify new predictive or diagnostic biomarkers/strategies for the identification of patients with atherosclerotic cardiovascular disease and hypertension who are at high risk of HF or are experiencing HF. In addition to focusing on ameliorating the prediction and diagnosis of HF, exploring optimal treatment strategies for atherosclerosis disease coexist hypertension in HF patients can also improve their long-term outcomes.
In this Research Topic, we aim to provide a forum for novel research findings on EndMT-related regulatory role in atherosclerosis and hypertension as well as ultimate HF. Studies on prediction, diagnosis, and therapy in HF patients along with atherosclerosis disease and hypertension are also welcome.
Suggested topics include, but are not limited to:
1) The regulatory role of EndMT in atherosclerosis disease, hypertension, and ultimate HF.
2) Novel predictive or diagnostic biomarkers/strategies on HF caused by atherosclerosis disease and hypertension.
3) The optimal therapies strategies for atherosclerosis disease coexist hypertension in HF patients.
We welcome submissions of Original Research articles, Reviews, Mini Review, Case Reports.
Heart failure (HF) is a principal cause of global mortality and disability. Atherosclerotic coronary disease and hypertension are two major risk factors for the incidence and progress of HF. Despite marked improvement in the management of the risk factors, the prevalence of HF continues to rise rapidly.
Understanding the pathogenesis of atherosclerosis and hypertension is essential to control the occurrence and progress of these diseases, which is helpful for reducing HF events caused by atherosclerosis and hypertension. Endothelial to mesenchymal transition (EndMT), characterized by decreasing endothelial properties and acquiring of mesenchymal features, plays a vital role in many cardiovascular diseases referring to the pathophysiology of atherosclerotic plaque formation and rupture, vascular or ventricular remodeling, etc. Furthermore, it is necessary to identify new predictive or diagnostic biomarkers/strategies for the identification of patients with atherosclerotic cardiovascular disease and hypertension who are at high risk of HF or are experiencing HF. In addition to focusing on ameliorating the prediction and diagnosis of HF, exploring optimal treatment strategies for atherosclerosis disease coexist hypertension in HF patients can also improve their long-term outcomes.
In this Research Topic, we aim to provide a forum for novel research findings on EndMT-related regulatory role in atherosclerosis and hypertension as well as ultimate HF. Studies on prediction, diagnosis, and therapy in HF patients along with atherosclerosis disease and hypertension are also welcome.
Suggested topics include, but are not limited to:
1) The regulatory role of EndMT in atherosclerosis disease, hypertension, and ultimate HF.
2) Novel predictive or diagnostic biomarkers/strategies on HF caused by atherosclerosis disease and hypertension.
3) The optimal therapies strategies for atherosclerosis disease coexist hypertension in HF patients.
We welcome submissions of Original Research articles, Reviews, Mini Review, Case Reports.
